|
|
Upfront Briefing
Two big reads landed within an hour of each other Tuesday, pointing in opposite directions. Novartis got the BTK class off the mat in multiple sclerosis. Alumis found out what a badly enrolled subgroup does to a lupus trial, and to a share price. Roche, meanwhile, wrote another China check — $75M up front for a preclinical trispecific, its second such pact this month. Cheap options on other people’s chemistry remain the trade of the year.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,631.5 |
(0.7%) |
11.3% |
| Nasdaq 100 |
29,077.2 |
(1.3%) |
15.4% |
| Russell 2000 |
2,920.1 |
(1.2%) |
16.4% |
| Healthcare (XLV) |
171.7 |
0.7% |
10.4% |
| Biotech (XBI) |
163.4 |
0.6% |
34.5% |
| Nasdaq Biotech (NBI) |
7,190.9 |
0.9% |
26.0% |
| Clinical Trials (BBC) |
52.9 |
(0.3%) |
40.6% |
|
- Healthcare was the only place to hide: XLV +0.7%, NBI +0.9% and XBI +0.6% against red across every major index, with Novartis up more than 4% after its remibrutinib REMODEL-1/-2 Phase 3 results published before the open, and Alumis down roughly 54% on its lupus miss.
- The broad tape ran on the Iran war restart: WTI settled at $90.22 (+5.2%) and Brent at $94.65 after strikes resumed in the Strait of Hormuz Monday night, taking the S&P 500 down 0.7% and the Russell 2000 down 1.2%. Rates barely flinched — the 10-year added 1.6bp to 4.812%, holding near its highest since January 2025 — while VIX rose 2.9% to 16.81 and TLT fell 0.8% on Tuesday, 1 September.
- Market data: U.S. cash close Tuesday, 1 September 2026.
The Big 3
|
1
|
Novartis remibrutinib wins in two large MS studies
|
- Remibrutinib, an oral BTK inhibitor, met its primary endpoint on annualised relapse rate in both REMODEL-1 and REMODEL-2, roughly 2,000 patients randomised against teriflunomide, with superiority on all key secondaries including MRI lesion reduction and no liver safety signal or Hy’s law cases. Full data goes to MSToronto2026 in October; filings follow.
- Why it matters: Two Phase 3 wins against teriflunomide across roughly 2,000 patients, with MRI lesion superiority and, the part that actually matters, no liver signal and no Hy’s law cases. Liver toxicity is the specific hurdle that has dogged rival BTK inhibitors from Sanofi and Roche, and it is why the class has carried a discount in MS. Novartis added more than 4% Tuesday. The soft spot is disability: 3mCDP was a trend and 6mCDP only nominally significant in a pooled analysis, so differentiation rests on safety and relapse rate until full data at MSToronto2026 in October. With Entresto past patent, Novartis needed this one to land.
- Source: BioPharma Dive
- More: STAT
|
|
2
|
Roche, Simcere sign trispecific T-cell engager pact
|
- Roche took exclusive global rights to SIM0660, a preclinical CD79a/CD19/CD3 trispecific T-cell engager from Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK), for $75M up front, up to $1.53B in total payments and tiered double-digit royalties on net sales.
- Why it matters: $75M up front against $1.53B in biobucks is a 4.9% cash ratio on a molecule that has never seen a patient, and that is now the going rate for China-origin preclinical assets. Roche has paid it twice this month. The dual CD79a/CD19 grip is the real thesis: it targets patients who have already failed CD20- or CD19-directed therapy, which is where Roche’s own Gazyva and much of the CAR-T field run out of road. Simcere has now out-licensed six assets for a combined $6.1B. Risk flag: COINS Act extension to biotech remains live, and every China BD&L signed this year carries that overhang.
-
Source:
Endpoints
-
More:
Fierce Biotech;
BioSpace
|
| 3 | Alumis drops 54% as lupus trial misses in all comers |
- The 408-patient Phase 2b LUMUS trial of envudeucitinib missed its primary endpoint, BICLA at Week 48, and its key secondaries in the overall SLE population; Alumis reported responses in a prespecified IFNGS-high subgroup it says was under-represented at enrolment, and will take that population to regulators for a Phase 3 discussion.
- Why it matters: A 408-patient Phase 2b that missed BICLA at Week 48 in all comers, rescued in narrative only by a prespecified IFNGS-high subgroup Alumis says was under-enrolled. Regulators rarely grant that appeal cheaply, and a biomarker-selected Phase 3 means a smaller, slower, costlier trial against Saphnelo, which already owns the interferon-directed lupus setting. Shares closed at $10.12, down roughly 54%, against a June cash balance near $500M. The psoriasis NDA is still tracking for Q4, and that filing, not lupus, is what the equity now rests on. TYK2 peers should read this as a class-expansion warning rather than a mechanism failure.
-
Source:
BioPharma Dive
- More: Fierce Biotech; Alumis
|
Everything Else that broke
- BioMarin and Ascendis struck binding terms ending their global patent fight over Yuviwel, dismissing the ITC Section 337 case and suits in four other jurisdictions; Ascendis pays 20% of U.S. net sales retroactive to first commercial sale and 18% in the EU, Brazil and South Korea through May 2030. — BioSpace
- GSK plans a September Phase 3 start for its newer-formulation mRNA flu vaccine after stronger Phase 2 immune responses. — Endpoints
- ARPA-H awarded up to $125M to five groups for on-demand custom RNA therapy manufacturing. — Endpoints
- Arsenal Biosciences is laying off most of its staff and seeking new homes for its assets in a pivot to in vivo CAR-T, a year after halving headcount. — Endpoints
- Novocure disclosed a cyberattack that exposed patient and employee data through unauthorised access to some of its information systems. — Fierce Biotech
- Medtronic recalled certain esophageal pH monitoring capsule delivery devices after 184 serious injuries linked to failures during deployment. — Fierce Biotech
- Veeva launched Falcon Safety, an agentic pharmacovigilance tool compatible with all E2B-compliant systems. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Roche licensed exclusive global rights to Simcere Zaiming’s preclinical CD79a/CD19/CD3 trispecific SIM0660 for $75M up front, up to $1.53B total and tiered double-digit royalties. — Endpoints
- Evotec and Plectonic paired BiTco CD2 bispecifics with LOGIBODY tech in a solid-tumor research collaboration. — PR
- RedHill acquired exclusive global and US commercialization rights to Ferring’s Rebyota and Clenpiq, adding two marketed GI products. — PR
VC / Private Financings
- Senticell closed an oversubscribed seed round approaching $7M led by The Venture City, Capital Factory, Scalpel Ventures and Evoce Capital, with additional participation from high-net-worth investors. — PR
IPOs / Follow-Ons
- Moderna closed a $2.6B offering of 0.00% convertible senior notes due 2032, upsized from $2.0B, at a 47.5% conversion premium to the $142.77 27 August close, with capped calls struck at a 175% premium; net proceeds of roughly $2.56B go to general corporate purposes, oncology and debt repayment. — BioSpace
- K Health said it is targeting an IPO by 2029 after its recent raise. — Endpoints
- Biopharma reverse mergers rose sharply this quarter, nearly rivalling traditional IPOs on BioSpace’s count. — BioSpace
Academic Corner - RT-qPCR artifact may inflate measured RNA knockdown in RNA-targeting CRISPR studies. — Nature Biotech
- Phase 3 NSABP B-59/GeparDouze missed event-free survival for atezolizumab in early triple-negative breast cancer. — Nature Medicine
- Review spotlights solute carrier transporters as emerging CNS drug targets. — Nature RDD
|
Two Phase 3 wins, one Phase 2b wipeout, and a preclinical molecule worth $1.53B.
— BioBucks Team
|
|
|
